Acadia Pharmaceuticals Inc. (ACAD) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE STIX, a powder formulation of DAYBUE oral solution, for the treatment of Rett syndrome in patients aged two years and older.
Rett syndrome is a rare neurodevelopmental disorder affecting approximately one in every 10,000 to 15,000 female births worldwide.
The powder formulation is expected to provide the same efficacy and safety profile as the DAYBUE oral solution approved in 2023.
The company said DAYBUE STIX will be available on a limited basis starting in the first quarter of 2026, with broader availability expected early in the second quarter, while the current oral solution formulation will remain available.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.